Could a common ED drug boost cancer immunotherapy?
NCT ID NCT03993353
First seen Feb 17, 2026 · Last updated May 22, 2026 · Updated 13 times
Summary
This study tested whether adding tadalafil (a drug often used for erectile dysfunction) to pembrolizumab (an immunotherapy) could help control advanced head and neck cancer. Seven adults with recurrent or metastatic disease participated. The goal was to check safety and see if the combination improves survival or slows cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.